PSA-negative/low prostate cancer cells: The true villains of CRPC?

Asian Journal of Andrology

Volumn 14, Issue 5, 2012, Pages 663-664

  Mulholland, David J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANDROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROTEIN P53;

ANDROGEN DEPRIVATION THERAPY; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL POPULATION; CELL SURVIVAL; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION;

EID: 84866250577     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2012.69     Document Type: Note

References (17)

1. Jemal A Siegel R Xu J Ward E. Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Siegel R Ward E Brawley O Jemal A. Cancer statistics 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
3. Chen Y Sawyers CL Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8: 440-8.
4. Chi KN Bjartell A Dearnaley D Saad F Schröder FH et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009; 56: 594-605.
5. Hobisch A Culig Z Radmayr C Bartsch G Klocker H et al. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995; 55: 3068-72.
6. Ruizeveld de Winter JA Janssen PJ Sleddens HM Verleun-Mooijman MC Trapman J et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am JPathol 1994; 144: 735-46.
7. Mostaghel EA Page ST Lin DW Fazli L Coleman IM et al. Intraprostatic androgens and androgenregulatedgene expression persist after testosterone suppression: Therapeutic implications for castrationresistant prostate cancer. Cancer Res 2007; 67:5033-41.
8. Shah RB Mehra R Chinnaiyan AM Shen R Ghosh D et al. Androgen-independent prostate cancer is Heterogeneous Group Of Diseases Lessons From Rapid Autopsy Program Heterogeneous Group Of Diseases Lessons From Rapid Autopsy Program. Cancer Res 2004; 64 9209-16.
9. Scher HI Beer TM Higano CS Anand A Taplin ME et al. Antitumour activity of MDV3100 in castrationresistant prostate cancer: A phase 1-2 study. Lancet2010; 375: 1437-46.
10. Roudier MP Vesselle H True LD Higano CS Ott SM et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003; 20: 171-80.
11. Qin J Liu X Laffin B Chen X Choy G et al. The PSA(2/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012; 10: 556-69.
12. Patrawala L Calhoun T Schneider-Broussard R Li H Bhatia B et al. Highly purified CD441 prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696-708.
13. Jeter CR Liu B Liu X Chen X Liu C et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 2011; 30: 3833-45.
14. Liu C Kelnar K Liu B Chen X Calhoun-Davis T et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211-5.
15. Germann M Wetterwald A Guzma'n-Ramirez N van der Pluijm G Culig Z et al. Stem-like cells with luminal progenitor phenotype survive castration inhuman prostate cancer. Stem Cells 2012; 30:1076-86.
16. Carver BS Chapinski C Wongvipat J Hieronymus H Chen Y et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-86.
17. Mulholland DJ Tran LM Li Y Cai H Morim A et al. Cell autonomous role ofPTEN in regulating castrationresistant prostate cancer growth. Cancer Cell 2011; 19: 792-804.